No association between endogenous LH and pregnancy in a GnRH antagonist protocol: Part II, recombinant FSH

Reproductive BioMedicine Online

Volumn 23, Issue 4, 2011, Pages 457-465

  Griesinger, George ^a   Shapiro, Daniel B ^b   Kolibianakis, Efstratios M ^c   Witjes, Han ^d   Mannaerts, Bernadette M ^e  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b REPRODUCTIVE BIOLOGY ASSOCIATES   (United States)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d Biostatistics and Research Decision Sciences   (Netherlands)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

combined analysis; endogenous LH; GnRH antagonist; pregnancy rates

Indexed keywords

CHORIONIC GONADOTROPIN; GANIRELIX; LUTEINIZING HORMONE; RECOMBINANT FOLLITROPIN;

ADULT; ARTICLE; CLINICAL PROTOCOL; FEMALE; FERTILIZATION IN VITRO; HUMAN; INTRACYTOPLASMIC SPERM INJECTION; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; OVARY HYPERSTIMULATION; OVULATION INDUCTION; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY RATE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SPONTANEOUS ABORTION; TREATMENT OUTCOME;

ABORTION, SPONTANEOUS; ADOLESCENT; ADULT; FEMALE; FOLLICLE STIMULATING HORMONE; GONADOTROPIN-RELEASING HORMONE; HUMANS; LUTEINIZING HORMONE; OVULATION INDUCTION; PREGNANCY; PREGNANCY RATE; RECOMBINANT PROTEINS;

EID: 80053560750     PISSN: 14726483     EISSN: 14726491     Source Type: Journal    
DOI: 10.1016/j.rbmo.2011.06.016     Document Type: Article

References (24)

1. J. Balasch, E. Vidal, J. Peñarrubia, R. Casamitjana, F. Carmona, M. Creus, F. Fábregues, and J.A. Vanrell Suppression of LH during ovarian stimulation: analysing threshold values and effects on ovarian response and the outcome of assisted reproduction in down-regulated women stimulated with recombinant FSH Hum. Reprod. 16 2001 1636 1643 (Pubitemid 32761742)
2. E. Bosch, E. Escudero, J. Crespo, C. Simón, J. Remohí, and A. Pellicer Serum luteinzing hormone in patients undergoing ovarian stimulation with gonadotropin-releasing hormone antagonists and recombinant follicle-stimulating hormone and its relationship with cycle outcome Fertil. Steril. 84 2005 1529 1532 (Pubitemid 41571915)
3. E. Bosch, E. Labarta, J. Crespo, C. Simón, J. Remohí, J. Jenkins, and A. Pellicer Circulating progesterone levels and ongoing pregnancy rates in controlled ovarian stimulation cycles for in vitro fertilization: analysis of over 4000 cycles Hum. Reprod. 25 2010 2092 2100
4. F.J. Broekmans, J. Kwee, D.J. Hendriks, B.W. Mol, and C.B. Lambalk A systematic review of tests predicting ovarian reserve and IVF outcome Hum. Reprod. Update 12 2006 685 718 (Pubitemid 44605509)
5. R.A. Cabrera, L. Stadtmauer, J.F. Mayer, W.E. Gibbons, and S. Oehninger Follicular phase serum levels of luteinising hormone do not influence delivery rates in vitro fertilization cycles down-regulated with a gonadotropin-releasing hormone agonist and stimulated with recombinant follicle-stimulating hormone Fertil. Steril. 83 2005 42 48 (Pubitemid 40094779)
6. Corifollitropin alfa Ensure Study Group Corifollitropin alfa for ovarian stimulation in IVF: a randomized trial in lower-body-weight women Reprod. Biomed. Online 21 2010 66 76
7. P. Devroey, R. Boostanfar, N.P. Koper, B.M. Mannaerts, P.C. Ijzerman-Boon, and B.C. Fauser on behalf of the ENGAGE Investigators, a double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol Hum. Reprod. 24 2009 3063 3072
8. K. Doody, P. Devroey, K. Gordon, H. Witjes, and B. Mannaerts LH concentrations do not correlate with pregnancy in rFSH/GnRH antagonist cycles Reprod. Biomed. Online 20 2010 565 567
9. Doody, K.J.; Devroey P.; Leader, A.; Witjes H.; Mannaerts, B.M.; 2011. No association between endogenous LH and pregnancy in a GnRH antagonist protocol: part I, corifollitropin alfa. Reprod. Biomed. Online 23, 449-456.
10. M.A. Esposito, K.T. Barnhart, C. Coutifaris, and P. Patrizio Role of periovulatory luteinising hormone concentrations during assisted reproductive technology cycles stimulated exclusively with recombinant follicle-stimulating hormone Fertil. Steril. 75 2001 519 524 (Pubitemid 32175666)
11. G. Griesinger, A. Dawson, A. Schultze-Mosgau, D. Finas, K. Dietrich, and R. Felberbaum Assessment of luteinizing hormone levels in the gonadotropin-releasing hormone-antagonist protocol Fertil. Steril. 85 2006 791 793 (Pubitemid 43261590)
12. J.A. Huirne, A.C. van Loenen, R. Schats, J. McDonnell, P.G. Hompes, J. Schoemaker, R. Homburg, and C.B. Lambalk Dose-finding study of daily GnRH antagonist for the prevention of premature LH surges in IVF/ICSI patients: optimal changes in LH and progesterone for clinical pregnancy Hum. Reprod. 20 2005 359 367 (Pubitemid 40277602)
13. P. Humaidan, L. Bungum, M. Bungum, and C.Y. Andersen Ovarian response and pregnancy outcome related to mid-follicular LH levels in women undergoing assisted reproduction with GnRH agonist down-regulation and recombinant FSH stimulation Hum. Reprod. 17 2002 2016 2021
14. E.M. Kolibianakis, K. Zikopoulos, J. Schiettecatte, J. Smitz, H. Tournaye, M. Camus, A.C. Van Steirteghem, and P. Devroey Profound LH suppression after GnRH antagonist administration is associated with a significantly higher ongoing pregnancy rate in IVF Hum. Reprod. 19 2004 2490 2496 (Pubitemid 39481272)
15. E.M. Kolibianakis, L. Kalogeropoulou, G. Griesinger, E.G. Papanikolaou, J. Papadimas, J. Bontis, and B.C. Tarlatzis Among patients treated with FSH and GnRH analogs for in vitro fertilization, is the addition of recombinant LH associated with the probability of live birth? A systematic review and meta-analysis Hum. Reprod. Update 13 2007 445 452 (Pubitemid 47299851)
16. P. Merviel, J.M. Antoine, E. Mathieu, F. Millot, J. Mandelbaum, and S. Uzan Luteinizing hormone concentrations after gonadotropin-releasing hormone antagonist administration do not influence pregnancy rates in in vitro fertilization-embryo transfer Fertil. Steril. 82 2004 119 125 (Pubitemid 38968786)
17. K. Nakagawa, S. Ohgi, A. Nakashima, T. Horikawa, R. Sugiyama, and H. Saito The ratio of late-follicular to mid-follicular phase LH concentrations efficiently predicts ART outcomes in women undergoing ART treatment with GnRH-agonist long protocol and stimulation with recombinant FSH J. Assist. Reprod. Genet. 25 2008 359 364
18. Nyboe Andersen, A.; Witjes, H.; Gordon, K.; Mannaerts, B. (in press). Predictive factors of ovarian response to controlled ovarian stimulation in a rFSH/GnRH antagonist protocol with and without oral contraceptive pretreatment. Hum. Reprod.
19. J.J.L. Oberyé, B.M.J.L. Mannaerts, J.A.M. Huisman, and C.J. Timmer Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Orgalutran). Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers Fertil. Steril. 72 1999 1006 1012
20. The European Orgalutran Study Group G. Borm, and B. Mannaerts Treatment with the gonadotropin-releasing hormone antagonist ganirelix in women undergoing controlled ovarian hyperstimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial Hum. Reprod. 15 2000 1490 1498
21. The European and Middle East Orgalutran Study Group Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing controlled ovarian hyperstimulation Hum. Reprod. 16 2001 644 651
22. The Ganirelix Dose-finding Study Group A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon) Hum. Reprod. 13 1998 3023 3031
23. The North American Ganirelix Study Group Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation Fertil. Steril. 75 2001 38 45
24. L.G. Westergaard, S.B. Laursen, and C.Y. Andersen Increased risk of early pregnancy loss by profound suppression of luteinising hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction Hum. Reprod. 15 2000 1003 1008 (Pubitemid 30251290)